Tools
Stock profile

BIOMARIN PHARMACEUTICAL INC (BMRN)

BMRN · Latest close $61.43 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$61.43
As of Nov 18, 2026
Tracked funds holding
7 of 149
2026 Q2 13F filings
Opened / added
0 / 5
vs previous quarter
Trimmed / exited
2
vs previous quarter

BIOMARIN PHARMACEUTICAL INC (BMRN) is held by 7 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 5 funds adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $1.2M sold). Latest close $61.43 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 2, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-1.2M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deep Track Capital · Viking Global Investors · Deerfield Management — 7 tracked funds hold BMRN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($1.2M). Insider trading

Often held alongside

ALNYLAM PHARMACEUTICALS, INC. (ALNY) · 3M CO (MMM) · Tradeweb Markets Inc. (TW) · Reddit, Inc. (RDDT) · Ferrari N.V. (RACE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deep Track Capital2.75%3,307,481ADDED (+187.6%) Q3 filed Nov 16
Viking Global Investors1.24%7,616,563ADDED (+7.9%) Q3 filed Nov 16
Deerfield Management0.80%1,332,836ADDED (+56.5%) Q3 filed Nov 16
Torray Investment Partners LLC0.60%77,705TRIMMED (-0.6%) Q3 filed Oct 30
Dodge & Cox Funds0.44%14,844,930ADDED (+1.9%) Q3 filed Nov 13
Thornburg Investment Management0.02%43,061ADDED (+305.9%) Q3 filed Nov 13
Edgewood Management0.01%10,000HELD Q3 filed Nov 12
Rubric Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +1.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

72.8348.742024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding565 of 8,857 filers
Long-only filers among them562
Change vs 2026 Q1+20 net · 534 entered · 514 exited
Shares reported, all filers193,669,110
Reported value, all filers$11.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$3.2B
Net income · FY2025$348.9M
Total assets · FY2025$7.6B
Shares outstanding193,573,759
Market cap (at latest close)$11.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 28, 2026.

Short interest

Shares short · Oct 15, 202612,050,657
Share of shares outstanding6.23%
Days to cover4.90

Shares short at recent settlements — Jul 31, 2026: 12.5M · Aug 14, 2026: 10.2M · Aug 31, 2026: 9.9M · Sep 15, 2026: 10.1M · Sep 30, 2026: 11.5M · Oct 15, 2026: 12.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 28, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 260 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 28, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($1.2M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 2, 2026Davis George EricEVP, Chief Legal OfficerSell17,557$66.28$1.2MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 2, 2026Davis George EricOfficer17,557$1.2MSep 2, 2026SEC filing
May 7, 2026Friberg Gregory ROfficer3,281$176.7KMay 7, 2026SEC filing
Mar 11, 2026Guyer Charles GregOfficer16,486$996.7KMar 11, 2026SEC filing
Feb 26, 2026Friberg Gregory ROfficer6,326$381.9KFeb 26, 2026SEC filing
Feb 26, 2026Davis George EricOfficer26,061$1.6MFeb 26, 2026SEC filing
May 20, 2025Burkhart ErinOfficer1,786$105.9KMay 20, 2025SEC filing
May 2, 2025Hubbard CristinOfficer273$17.7KMay 2, 2025SEC filing
Mar 19, 2025Burkhart ErinOfficer1,295$92.6KMar 19, 2025SEC filing
Mar 6, 2025Guyer Charles GregOfficer7,034$501.4KMar 6, 2025SEC filing
Feb 24, 2025Burkhart ErinOfficer1,344$91.9KFeb 24, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Apr 29, 2026Vanguard Capital ManagementSC 13G10,113,2195.2%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A17,560,7519.1%Dec 31, 2025SEC filing
Nov 14, 2025VIKING GLOBAL INVESTORS LPSC 13G/A8,322,1794.3%Sep 30, 2025SEC filing
Aug 14, 2025PRIMECAP MANAGEMENT CO/CA/SC 13G/A15,795,3838.2%Jun 30, 2025SEC filing
Aug 14, 2025VIKING GLOBAL INVESTORS LPSC 13G/A12,288,6116.4%Jun 30, 2025SEC filing
May 13, 2025Capital Research Global InvestorsSC 13G/A9,150,6554.8%Mar 31, 2025SEC filing
Apr 29, 2025BlackRock, Inc.SC 13G/A20,620,17910.8%Mar 31, 2025SEC filing
Feb 13, 2025Capital Research Global InvestorsSC 13G/A12,991,7726.8%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 146 Lobbying Disclosure Act filings named this company as client, 2007–2026; most common issues: Health Issues (116), Medicare/Medicaid (69), Taxation/Internal Revenue Code (63).

Federal contracts: $117.4K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$26.2K
FY2022$157.8K
FY2023$-41.9K
FY2024$-24.7K
FY2025$0
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
36C26322N0466Department of Veterans Affairs$117.4KFeb 4, 2022
36C25922F0039Department of Veterans Affairs$0Oct 13, 2021
36C25921F0394Department of Veterans Affairs$0Jul 29, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Cash Flow (FCF) — Latest FCF: $725.0M · FCF yield: 6.4% · Positive FCF years: 3

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.55 · Operating cash flow: $828.0M · Net income: $348.9M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together250.0%-6.8%+5.8%-12.5%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BMRN — ranked by lift, the co-holding pattern described in Methodology: ALNYLAM PHARMACEUTICALS, INC. (ALNY) · 3M CO (MMM) · Tradeweb Markets Inc. (TW) · Reddit, Inc. (RDDT) · Ferrari N.V. (RACE) · PFIZER INC (PFE) · HOME DEPOT, INC. (HD) · AbbVie Inc. (ABBV).

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 6, 20262.02 Results of Operations and Financial ConditionSEC filing
Sep 30, 20261.01 Entry into a Material Definitive AgreementSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ALNYLAM PHARMACEUTICALS, INC. (ALNY) · Track Record: how the signals scored · Practice timing on BMRN

One email a week: the week’s new filings and research. Subscribe free

← BMO  ·  BMY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.